Anavex Life Sciences Corp.
Description Anavex Life Sciences Corp., a development stage biopharmaceutical company, engages in the discovery and development of novel drugs for the treatment of neurological diseases and cancer utilizing its proprietary drug discovery SIGMACEPTOR platform. Its lead drug candidate includes ANAVEX 2-73, which has completed Phase I single ascending dose clinical trial for the treatment of Alzheimers disease. The companys product candidates also comprise ANAVEX 19-144, a drug candidate that controls seizures and the epileptogenesis process in the animals; ANAVEX 1-41, a sigma-1 agonist that is primarily used for neuroprotective application; and ANAVEX 7-1037 for the treatment of prostate cancer. The company was founded in 2004 and is based in Vancouver, Canada. To view the detailed information, you need to SUBSCRIBE with us. |
 |